High hopes for new Alzheimer's drug
It's got a big name -- bapineuzumab -- but a new Alzheimer's drug could also have a big payoff. With projections in the billions, it could be the highest grossing drug in history. Janet Babin reports.
River of pills (iStockPhoto)
More on Health, Innovation
TEXT OF STORY
Kai Ryssdal: Drugmakers are constantly on the lookout for their next blockbuster opportunity and two firms on the cutting edge of Alzheimer's research are getting close.
Janet Babin has more from the Marketplace Innovations Desk at North Carolina Public Radio.
Janet Babin: Elan and Wyeth's new Alzheimer's drug has a tongue twister of a name -- it's called bapineuzumab. It works by attacking the plaque deposits in the brain that are associated with Alzheimer's. It shows the most promise for people without an inherited Alzheimer's marker -- that's about 60 percent of us.
If the final trial goes well, analyst Eric Snyder with Mehta Partners says bapineuzumab could become the biggest selling drug of all time.
Eric Snyder: Clearly it's a $1 billion product or more. People are saying it could be $5 billion, it could be $13 billion.
But Snyder's still cautious about bapineuzumab's market potential. A previous trial with a drug that used a similar approach had to be stopped. Some patients came down with abnormal swelling of the brain.
And then there's the competition. Myriad Genetics also has a breakthrough Alzheimer's drug on the way. More data about both drugs will be released at an Alzheimer's conference next month.Snyder: Even though the drug seems very promising, I personally am concerned about the safety risks.
I'm Janet Babin for Marketplace.
Comments
Comment | Refresh
Post a Comment: Please be civil, brief and relevant.
Email addresses are never displayed, but they are required to confirm your comments. All comments are moderated. Marketplace reserves the right to edit any comments on this site and to read them on the air if they are extra-interesting. Please read the Comment Guidelines before posting.
You must be 13 or over to submit information to American Public Media. The information entered into this form will not be used to send unsolicited email and will not be sold to a third party. For more information see Terms and Conditions and Privacy Policy.